We wanted to assess whether the herein identified sphingolipid/EMT-associated 35-gene signature, attributed to TGFbeta + TNFalpha stimulation condition, can be similarly detected in other cell-based models or treatment conditions and, importantly, in neoplastic tissues from patients with various types of lung malignancies and/or with other cancer types. This evidence concerns the gene TGFB1 and cancer.